DDF Summit: Drug Delivery & Formulation, August 28-29, 2017, Boston

Lots of big name companies there......BiOasis will have great opportunity to mingle here. Reinhard Gabathuler is on the schedule for Monday August 28. Also, Quentin Smith is speaking on Monday August 28th too....Texas Tech University collaborator of biOasis. Just Gabathuler's and Smith's conference profiles make mention of blood brain barrier......though many, many of the companies attending would surely be interested in BBB technologies.

Reinhard Gabathuler, Chief Scientist biOasis Technologies Inc.

"Protein vectors to cross the BBB for the delivery of therapeutic concentration of biologics"

• Essential nutrients cross the Blood-Brain Barrier by Receptor Mediated Transcytosis?

• Incorporation of New Vectors into Therapeutics to cross the Blood-Brain Barrier?

• Delivery of therapeutic concentration of biologics to the CNS

• Delivery of Therapeutics to the Adequate Intracellular Compartment of Brain Cells

Quentin Roberts Smith, Dean and University Distinguished Professor, Texas Tech University Health Sciences Center

"New Approaches to Advance Therapeutic Drug Delivery across the Blood-Brain Barrier to Brain and Brain Tumours"

• The blood-brain barrier restrict the brain delivery of most currently active anticancer agents used in the treatment of brain tumours. • The magnitude of this restriction is extremely large (50-200 fold) for some of the most commonly used agents cytotoxic agents (paclitaxel, doxorubicin, vinorelbine,) and newer molecularly-target agents. • In only a very small subset (<5%) of brain metastases is the barrier sufficiently compromised to allow marked drug accumulation. • This restriction was found in matching human brain metastases. • This drug delivery compromise can be overcome in brain metastases using several approaches, including drug agents which show poor affinity for barrier active efflux transport, enhanced barrier passive permeability, elevated active efflux, or molecularly targeting mechanism, such as those in using LRP, transferrin, insulin receptor, or other mechanisms.